Belite Bio [BLTE] vs Bio-Techne [TECH] Detailed Stock Comparison
Belite Bio
NASDAQ
Loading...
Bio-Techne
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Belite Bio wins in 6 metrics, Bio-Techne wins in 9 metrics, with 0 ties. Bio-Techne appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Belite Bio | Bio-Techne | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -64.07 | 136.85 | Belite Bio |
| Price-to-Book Ratio | 16.44 | 5.08 | Bio-Techne |
| Debt-to-Equity Ratio | 0.00 | 23.14 | Belite Bio |
| PEG Ratio | -1.05 | -0.96 | Belite Bio |
| EV/EBITDA | -68.72 | 30.42 | Belite Bio |
| Profit Margin (TTM) | 0.00% | 6.02% | Bio-Techne |
| Operating Margin (TTM) | 0.00% | 36.30% | Bio-Techne |
| EBITDA Margin (TTM) | N/A | 36.30% | N/A |
| Return on Equity | -17.33% | 3.68% | Bio-Techne |
| Return on Assets (TTM) | -11.68% | 6.30% | Bio-Techne |
| Free Cash Flow (TTM) | $-29.39M | $256.55M | Bio-Techne |
| Dividend Yield | N/A | 0.79% | N/A |
| 1-Year Return | 41.18% | -15.59% | Belite Bio |
| Price-to-Sales Ratio (TTM) | N/A | 8.04 | N/A |
| Enterprise Value | $2.45B | $10.07B | Bio-Techne |
| EV/Revenue Ratio | N/A | 8.26 | N/A |
| Gross Profit Margin (TTM) | N/A | 62.72% | N/A |
| Revenue per Share (TTM) | $0 | $8 | Bio-Techne |
| Earnings per Share (Diluted) | $-1.55 | $0.46 | Bio-Techne |
| Beta (Stock Volatility) | -1.47 | 1.48 | Belite Bio |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Belite Bio vs Bio-Techne Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Belite Bio | 3.31% | 6.99% | 15.69% | 33.21% | 40.29% | 20.60% |
| Bio-Techne | -1.64% | 18.55% | 14.43% | 20.14% | 18.37% | -13.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Belite Bio | 41.18% | 181.24% | 184.41% | 130.86% | 417.56% | 417.56% |
| Bio-Techne | -15.59% | -12.43% | -6.78% | 160.83% | 298.20% | 351.64% |
News Based Sentiment: Belite Bio vs Bio-Techne
Belite Bio
News based Sentiment: POSITIVE
Belite Bio experienced continued positive momentum this month, with a significant stock price increase and optimistic analyst ratings. While the company still lacks revenue, its strong cash position and progress in clinical trials are driving investor enthusiasm. The increase in shares outstanding remains a factor to watch, but overall the month's developments suggest a positive outlook.
Bio-Techne
News based Sentiment: MIXED
Bio-Techne experienced a strong month with significant stock gains fueled by positive earnings and a broader healthcare sector rally. However, analyst concerns regarding organic growth and declining free cash flow create a mixed investment picture, requiring investors to carefully weigh the potential risks and rewards.
Performance & Financial Health Analysis: Belite Bio vs Bio-Techne
| Metric | BLTE | TECH |
|---|---|---|
| Market Information | ||
| Market Cap | $2.48B | $9.80B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 51,090 | 3,192,556 |
| 90 Day Avg. Volume | 47,930 | 2,630,039 |
| Last Close | $78.10 | $61.92 |
| 52 Week Range | $49.00 - $86.53 | $46.01 - $80.80 |
| % from 52W High | -9.74% | -23.37% |
| All-Time High | $86.53 (Nov 11, 2024) | $135.96 (Sep 20, 2021) |
| % from All-Time High | -9.74% | -54.46% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.04% |
| Quarterly Earnings Growth | N/A | 0.04% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.06% |
| Operating Margin (TTM) | 0.00% | 0.36% |
| Return on Equity (TTM) | -0.17% | 0.04% |
| Debt to Equity (MRQ) | 0.00 | 23.14 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $4.60 | $12.38 |
| Cash per Share (MRQ) | N/A | $1.04 |
| Operating Cash Flow (TTM) | $-30,549,000 | $287.56M |
| Levered Free Cash Flow (TTM) | $-36,144,000 | $313.92M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.79% |
| Last 12-Month Dividend | $0.00 | $0.40 |
Valuation & Enterprise Metrics Analysis: Belite Bio vs Bio-Techne
| Metric | BLTE | TECH |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -64.07 | 136.85 |
| Forward P/E | -78.75 | 28.74 |
| PEG Ratio | -1.05 | -0.96 |
| Price to Sales (TTM) | N/A | 8.04 |
| Price to Book (MRQ) | 16.44 | 5.08 |
| Market Capitalization | ||
| Market Capitalization | $2.48B | $9.80B |
| Enterprise Value | $2.45B | $10.07B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 8.26 |
| Enterprise to EBITDA | -68.72 | 30.42 |
| Risk & Other Metrics | ||
| Beta | -1.47 | 1.48 |
| Book Value per Share (MRQ) | $4.60 | $12.38 |
Financial Statements Comparison: Belite Bio vs Bio-Techne
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BLTE | TECH |
|---|---|---|
| Revenue/Sales | $0 | $316.96M |
| Cost of Goods Sold | N/A | $118.15M |
| Gross Profit | N/A | $198.81M |
| Research & Development | $9.40M | $26.03M |
| Operating Income (EBIT) | $-15.52M | $116.69M |
| EBITDA | $-15.52M | $6.43M |
| Pre-Tax Income | $-14.28M | $-22.86M |
| Income Tax | $0 | $-5.18M |
| Net Income (Profit) | $-14.28M | $-17.68M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BLTE | TECH |
|---|---|---|
| Cash & Equivalents | N/A | $162.19M |
| Total Current Assets | $159.29M | $608.30M |
| Total Current Liabilities | N/A | $175.85M |
| Long-Term Debt | N/A | $429.96M |
| Total Shareholders Equity | $158.07M | $1.92B |
| Retained Earnings | N/A | $1.07B |
| Property, Plant & Equipment | N/A | $73.40M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BLTE | TECH |
|---|---|---|
| Operating Cash Flow | N/A | $7.55M |
| Capital Expenditures | N/A | $-4.89M |
| Free Cash Flow | N/A | $93.31M |
| Debt Repayment | N/A | $-50.00M |
| Common Stock Repurchase | N/A | $-100.06M |
Short Interest & Institutional Ownership Analysis
| Metric | BLTE | TECH |
|---|---|---|
| Shares Short | 197,932 | 5.27M |
| Short Ratio | 4.80 | 2.59 |
| Short % of Float | 0.01% | 0.04% |
| Average Daily Volume (10 Day) | 51,090 | 3,192,556 |
| Average Daily Volume (90 Day) | 47,930 | 2,630,039 |
| Shares Outstanding | 31.83M | 154.97M |
| Float Shares | 15.17M | 153.71M |
| % Held by Insiders | 0.50% | 0.00% |
| % Held by Institutions | 0.01% | 1.04% |
Dividend Analysis & Yield Comparison: Belite Bio vs Bio-Techne
| Metric | BLTE | TECH |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $0.40 |
| Last 12-Month Dividend Yield | N/A | 0.79% |
| 3-Year Avg Annual Dividend | $0.00 | $0.35 |
| 3-Year Avg Dividend Yield | N/A | 0.12% |
| 3-Year Total Dividends | $0.00 | $1.04 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |